Biomea Fusion Shares Up 20% Premarket; Co Announced Late Friday, Data From Phase II Study Of BMF-219 In Patients With Type 2 Diabetes Mellitus Showed 100 Mg Cohort 3 Demonstrated A 90% Response Rate And 70% Maintained Or Improved Time In (Normal Glucose) Range, While Off-treatment
Portfolio Pulse from Charles Gross
Biomea Fusion's stock is up 20% premarket after announcing positive Phase II study data for BMF-219 in Type 2 Diabetes Mellitus patients. The 100 mg Cohort 3 showed a 90% response rate and 70% maintained or improved time in the normal glucose range.
June 26, 2023 | 9:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomea Fusion's stock price is up 20% premarket due to positive Phase II study results for BMF-219 in Type 2 Diabetes Mellitus patients.
The positive Phase II study results for BMF-219 in Type 2 Diabetes Mellitus patients indicate a potential successful treatment option, which could lead to increased demand for the drug and higher revenues for Biomea Fusion. This news directly impacts BMEA's stock price, causing it to rise 20% premarket.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100